Multiple Myeloma
Conditions
Keywords
Multiple Myelonoma, Romidepsin, Bortezomib
Brief summary
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.
Interventions
DRUGBortezomib
Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion. Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
DRUGRomidepsin
Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
Sponsors
Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must fulfill all of the following criteria to be eligible for study participation: * Male or female patients aged ≥ 18 years old * Has given voluntary written informed consent before any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care * Previously diagnosed with multiple myeloma (MM) based on standard criteria as follows: * Major criteria: 1. Plasmacytomas on tissue biopsy. 2. Bone marrow plasmacytosis (\>30% plasma cells). 3. Monoclonal immunoglobulin spike on serum electrophoresis IgG \>3.5 g/dL or IgA \>2.0 g/dL; kappa or lambda light chain excretion \>1 g/day on 24 hour urine protein electrophoresis * Minor criteria: 1. Bone marrow plasmacytosis (10 to 30% plasma cells) 2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria 3. Lytic bone lesions. 4. Normal IgM \<50 mg/dL, IgA \<100 mg/dL or IgG \<600 mg/dL Any of the following sets of criteria will confirm the diagnosis of MM: * Any two of the major criteria * Major criterion 1 plus minor criterion 2, 3, or 4. * Major criterion 3 plus minor criterion 1 or 3. * Minor criteria 1, 2, and 3 or 1, 2, and 4. * Currently has MM with: o Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \>=1 gm/dL and/or urine monoclonal immunoglobulin spike of \>=200 mg/24 hours, or evidence of lytic bone disease * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Life-expectancy \> 3 months * All women of childbearing potential must use an effective barrier method of contraception. Male patients should use a barrier method of contraception during the treatment period and for 3 months thereafter * Patients must meet the following laboratory criteria at Baseline (Day 1 of Cycle 1, before study drug administration): * Platelet count ≥ 100\*10\^9/L * Absolute neutrophil count ≥ 1.5\*10\^9/L * OR if the bone marrow is extensively infiltrated * Platelet count ≥ 75\*10\^9/L * Absolute neutrophil count ≥ 1.0\*10\^9/L * Patients must meet the following laboratory criteria at the Screening visit conducted within 14 days of enrollment (Day 1, Cycle 1): * o Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 3.0\*upper limit of normal (ULN) * Serum bilirubin ≤ 2.0\*ULN * Calculated or measured creatinine clearance: ≥30 mL/minute. Patient with a creatinine \>10mL/min and \<30 mL/min due to significant myelomatous involvement of the kidneys may be enrolled in the study after receipt of approval from the lead investigator and sponsor * Serum potassium ≥ 3.8 mmol/L * Serum magnesium \>1.8 mg/dL * Serum phosphorus ≥ lower limit of normal (LLN)
Exclusion criteria
Patients are ineligible for entry if any of the following criteria are met: * Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or thalidomide, lenalidomide, arsenic trioxide, bortezomib, or glucocorticosteroids within 3 weeks prior to the first dose of romidepsin * Prior major surgery within 3 weeks prior to the first day of treatment * Use of any investigational agent within 4 weeks of study entry * Prior therapy with romidepsin * Any known cardiac abnormalities such as: * Congenital long QT syndrome; * QTc interval ≥ 500 milliseconds; * Myocardial infarction within 6 months of Day 1. Subjects with a history of myocardial infarction between 6 and 12 months prior to the first day of cycle one who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate; * Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min); * Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present; * An ECG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present; * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by Multi Gated Acquisition Scan (MUGA scan) or \<50% by echocardiogram and/or MRI; * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD); * Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes; * Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or * Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers) * POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) * Plasma cell leukemia * Primary amyloidosis * Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) * Severe hypercalcemia, i.e., serum calcium ≥14 mg/dL (3.5 mmol/L) * Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Other concurrent severe and/or uncontrolled medical or psychiatric conditions. * Concomitant use of drugs that may cause a prolongation of the QTc * Concomitant use of CYP3A4 inhibitors * Patients who have hypersensitivity to bortezomib, boron or mannitol * Patients who are pregnant or breast-feeding * Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Count of Participant Best Overall Response As Assessed by the Investigator | up to 8 months | Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other. Stable Disease: Less than MR, but not PD Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) of Romidepsin based on plasma samples. |
| Maximum Observed Concentration (Cmax) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | Maximum observed concentration of Romidepsin |
| Time to Maximum Observed Concentration (Tmax) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | Time to maximum observed concentration of Romidepsin |
| Terminal Half-life (t1/2) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | Terminal half-life of Romidepsin |
| Total Clearance (CL) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | Total clearance of Romidepsin |
| Participants With Treatment-emergent Adverse Events (TEAEs) | up to 9 months | Counts of participants with TEAEs, and subset by relation to drug, grade of severity, serious, TEAEs leading to discontinuation or leading to death. AEs were graded for severity according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE), V 3.0: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe (prevents normal everyday activities); Grade 4: Life-threatening or disabling; Grade 5: Death. |
| Kaplan Meier Estimate for Time to Progression Assessed by the Investigator | up to month 8 | Time to progression of disease is defined as the time from initiation of therapy to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia. |
| Kaplan Meier Estimate for Time to Response Assessed by the Investigator | up to month 8 | The time to the first response is defined as the time from the initiation of therapy to the first evidence of a confirmed response (complete response, very good partial response, partial response or minimal response). Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other. |
| Kaplan Meier Estimate for Duration of Response Assessed by the Investigator | up to month 8 | Duration of response is defined as the time from first response to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia. |
| Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator | up to month 8 | Progression-free survival is the time from initiation of therapy to progressive disease, removal from study for any reason, death from any cause, or the last follow-up visit, whichever occurs first. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia. |
| Kaplan Meier Estimates for Overall Survival | up to month 8 | Overall survival is the time from initiation of therapy to death from any cause. |
| Total Volume of Distribution (Vz) | Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion | Total volume of distribution of Romidepsin |
Countries
United States
Participant flow
Pre-assignment details
Stratum 1 (bortezomib resistant) had 19 participants. Stratum 2 (non-bortezomib resistant) had 13 participants.
Participants by arm
| Arm | Count |
|---|---|
| Romidepsin + Bortezomib Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.
Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles. | 32 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 6 |
| Overall Study | Physician Decision | 4 |
| Overall Study | Progressive disease | 18 |
| Overall Study | Protocol Violation | 1 |
| Overall Study | Withdrawal by Subject | 2 |
Baseline characteristics
| Characteristic | Romidepsin + Bortezomib |
|---|---|
| Age, Continuous | 63.7 years STANDARD_DEVIATION 8.11 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Status 0 | 12 participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Status 1 | 14 participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Status 2 | 6 participants |
| Race/Ethnicity, Customized Asian | 2 participants |
| Race/Ethnicity, Customized Black or African American | 2 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 2 participants |
| Race/Ethnicity, Customized Other | 2 participants |
| Race/Ethnicity, Customized White | 24 participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 32 / 32 |
| serious Total, serious adverse events | 14 / 32 |
Outcome results
Primary
Count of Participant Best Overall Response As Assessed by the Investigator
Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other. Stable Disease: Less than MR, but not PD Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia.
Time frame: up to 8 months
Population: Intent-to-Treat (ITT) population of patients defined as all patients who receive at least one dose of romidepsin and bortezomib. However efficacy data was not analyzed due to the early termination of the study.
Secondary
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) of Romidepsin based on plasma samples.
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Romidepsin + Bortezomib | Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) | 1209.1 ng*hr/mL | Geometric Coefficient of Variation 29.4 |
| Romidepsin 10 mg/m^2 + Bortezomib | Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) | 1149.5 ng*hr/mL | Geometric Coefficient of Variation 22.2 |
Secondary
Kaplan Meier Estimate for Duration of Response Assessed by the Investigator
Duration of response is defined as the time from first response to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
Time frame: up to month 8
Population: Intent to treat population. However efficacy data was not analyzed due to the early termination of the study.
Secondary
Kaplan Meier Estimate for Time to Progression Assessed by the Investigator
Time to progression of disease is defined as the time from initiation of therapy to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
Time frame: up to month 8
Population: Intent to treat population. Analysis was not performed due to early termination of the study.
Secondary
Kaplan Meier Estimate for Time to Response Assessed by the Investigator
The time to the first response is defined as the time from the initiation of therapy to the first evidence of a confirmed response (complete response, very good partial response, partial response or minimal response). Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other.
Time frame: up to month 8
Population: Intent to treat population. However efficacy data was not analyzed due to the early termination of the study.
Secondary
Kaplan Meier Estimates for Overall Survival
Overall survival is the time from initiation of therapy to death from any cause.
Time frame: up to month 8
Population: Intent to treat population. However efficacy data was not analyzed due to the early termination of the study.
Secondary
Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator
Progression-free survival is the time from initiation of therapy to progressive disease, removal from study for any reason, death from any cause, or the last follow-up visit, whichever occurs first. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
Time frame: up to month 8
Population: Intent to treat population. However efficacy data was not analyzed due to the early termination of the study.
Secondary
Maximum Observed Concentration (Cmax)
Maximum observed concentration of Romidepsin
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Romidepsin + Bortezomib | Maximum Observed Concentration (Cmax) | 913.9 ng/mL | Geometric Coefficient of Variation 21.4 |
| Romidepsin 10 mg/m^2 + Bortezomib | Maximum Observed Concentration (Cmax) | 1002.7 ng/mL | Geometric Coefficient of Variation 20.6 |
Secondary
Participants With Treatment-emergent Adverse Events (TEAEs)
Counts of participants with TEAEs, and subset by relation to drug, grade of severity, serious, TEAEs leading to discontinuation or leading to death. AEs were graded for severity according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE), V 3.0: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe (prevents normal everyday activities); Grade 4: Life-threatening or disabling; Grade 5: Death.
Time frame: up to 9 months
Population: Safety population of participants who took at least one dose of drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 serious TEAE | 14 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 TEAE | 32 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 drug-related TEAE | 30 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 Romidepsin-related TEAE | 28 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 Bortezomib-related TEAE | 30 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 >=Grade 3 TEAE | 28 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 Grade 4 TEAE | 5 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 TEAE leading to discontinuation | 6 participants |
| Romidepsin + Bortezomib | Participants With Treatment-emergent Adverse Events (TEAEs) | At least 1 TEAE leading to death | 2 participants |
Secondary
Terminal Half-life (t1/2)
Terminal half-life of Romidepsin
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Romidepsin + Bortezomib | Terminal Half-life (t1/2) | 4.1 hr | Geometric Coefficient of Variation 11 |
| Romidepsin 10 mg/m^2 + Bortezomib | Terminal Half-life (t1/2) | 3.6 hr | Geometric Coefficient of Variation 41.7 |
Secondary
Time to Maximum Observed Concentration (Tmax)
Time to maximum observed concentration of Romidepsin
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Romidepsin + Bortezomib | Time to Maximum Observed Concentration (Tmax) | 1.04 hr |
| Romidepsin 10 mg/m^2 + Bortezomib | Time to Maximum Observed Concentration (Tmax) | 0.58 hr |
Secondary
Total Clearance (CL)
Total clearance of Romidepsin
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Romidepsin + Bortezomib | Total Clearance (CL) | 11.3 L/hr | Geometric Coefficient of Variation 26.9 |
| Romidepsin 10 mg/m^2 + Bortezomib | Total Clearance (CL) | 16.4 L/hr | Geometric Coefficient of Variation 31.5 |
Secondary
Total Volume of Distribution (Vz)
Total volume of distribution of Romidepsin
Time frame: Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
Population: A subset of participants from the lead investigator's site had PK samples taken.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Romidepsin + Bortezomib | Total Volume of Distribution (Vz) | 66.5 L | Geometric Coefficient of Variation 23.4 |
| Romidepsin 10 mg/m^2 + Bortezomib | Total Volume of Distribution (Vz) | 85.9 L | Geometric Coefficient of Variation 66.8 |